Document is current
Any future updates will be listed below
-
Authors
Fernando, Wasundara
Cruickshank, Brianne M.
Arun, Raj Pranap
MacLean, Maya R.
Cahill, Hannah F.
Morales-Quintanilla, Fiorella
Dean, Cheryl A.
Wasson, Marie-Claire D.
Dahn, Margaret L.
Coyle, Krysta M.
Walker, Olivia L. https://orcid.org/0000-0003-3173-1407
Power Coombs, Melanie R.
Marcato, Paola https://orcid.org/0000-0001-8619-283X
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (PJT 162313, PJT 191871)
- License Information
-
More Information
Article History
Received: 2 May 2024
Revised: 29 August 2024
Accepted: 2 September 2024
First Online: 9 September 2024
Competing interests
: The authors declare no competing interests.
: The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations. For all mouse experiments (including all cell line and PDX tumor xenograft experiments), approval has been obtained from the Dalhousie University Committee on Laboratory Animals, which adheres to the ethical standards according to the Declaration of Helsinki and to the Canadian Council on Animal Care standards. The mouse work was approved under protocol numbers 19-013 and 21-011 (“Investigating molecular pathways of breast cancer progression”). As described by Zhang et al. [], The PDX-AIM Core of Baylor College of Medicine that supplied the PDX () was obtained from a tumor sample of a patient that was recruited from clinics in the Baylor College of Medicine (BCM) Breast Center (Houston, TX) and Ben Taub General Hospital (Houston, TX) under Institutional Review Board-approved protocols. The PDX used in the experiments was generated from a patient with written informed consent under Institutional Review Board Approved protocols.
